Hero Image

About Us

Our history


A genetics discovery by Professors Jay and Maureen Neitz led to the hypothesis that contrast signaling in the retina may play a role in myopia development


Creation of SightGlass Vision. SGV’ sole focus has been on delivering science based treatments to address the myopia epidemic through research, development, and clinical progress.


Start of the CYPRESS study, our pivotal 3-year clinical trial to evaluate the safety and efficacy of our DOT™ spectacle lenses.

February 2021

EssilorLuxottica and CooperCompanies announce Joint Venture for acquisition of SightGlass Vision.


First commercialization of the DOT in the Netherlands.


SightGlass Vision Joint Venture becomes operational.

Who we are

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research based on the unique contrast theory.

Its unique Diffusion Optics Technology™️ is based on these ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to mimic more natural contrast on the retina — a method intended to reduce myopia progression in children.

The treatment has completed the three years pivotal multisite clinical study.

Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.

Please note that our products are not available for sale or distribution in every country in the world.
Our products are not available for sale in the U.S.